Peer-influenced content. Sources you trust. No registration required. This is HCN.

Sintilimab Plus Chemo Prolongs Survival in Advanced Non-Small Cell Lung CancerSintilimab Plus Chemo Prolongs Survival in Advanced Non-Small Cell Lung Cancer

The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form